Companies cannot rely on their own definition of “usual and customary” when determining prices to reimburse federal drug programs, the U.S. Supreme Court unanimously ruled Thursday in a whistleblower case brought under the False Claims Act.
“There are probably a lot of disappointed defense lawyers today,” said Phillips & Cohen partner Stephen Hasegawa in a statement sent shortly after the opinion was released in Schutte v. SuperValu.
